Stem Cell Transplantation Most Cost-Effective Curative Option for Sickle Cell Disease, Study Finds
核心洞察
A new decision-analytic modeling study published in Blood finds NMAC-HID allo-HSCT delivers the best clinical value among curative sickle cell treatments.
Gene therapy accrued the highest QALYs (22.1) at $2.75 million, while stem cell transplant achieved 20.1 QALYs at $1.15 million, and standard care yielded 14.3 QALYs at $1.22 million.
Researchers determined gene therapy would need a 66% to 71% price reduction — to $627,000–$740,000 — to be cost-competitive with stem cell transplantation in the United States.
A first-of-its-kind cost-effectiveness analysis comparing all three long-term treatment strategies for sickle cell disease (搜索) in adults has found that non-myeloablative haploidentical allogeneic stem cell transplantation (NMAC-HID allo-HSCT) offers the best clinical value for cost, outperforming both gene therapy and standard of care. The study, published in Blood, arrives at a pivotal moment as curative options expand but health systems grapple with their financial implications.
"Gene therapy is an incredible immune innovation, but it comes with an astronomical cost," said lead study author George Goshua, MD, SM, FACP, assistant professor of medicine in the section of medical oncology and hematology at Yale School of Medicine and Yale Cancer Center, and principal investigator at the Goshua Lab. "Recent prospective studies suggest that stem cell transplantation is now safer and more efficacious than before for people living with sickle cell disease (搜索), but data on its cost-effectiveness, especially in the era of gene therapy, have been limited."
Disease Burden and Treatment Landscape
Sickle cell disease (搜索) is the most common inherited blood disorder, affecting nearly 8 million people worldwide and approximately 100,000 individuals in the United States. It is more prevalent in people with ancestral origins in regions where malaria is common, including sub-Saharan Africa, the Indian subcontinent, the Arabian peninsula, and parts of the Mediterranean. The disorder is characterized by abnormally shaped blood cells that can become lodged in blood vessels, blocking blood flow and leading to organ damage, infection, and episodes of severe pain.
Standard of care management includes hydroxyurea, pain management, and blood transfusions. However, individuals can also achieve lifelong remission through stem cell transplantation or gene therapy, both of which work to replace defective blood-forming stem cells with healthy ones capable of producing normal, non-sickled red blood cells.
NMAC-HID allo-HSCT uses reduced-intensity conditioning, involving less chemotherapy and radiation to prepare the bone marrow, making it less toxic than traditional transplant and better suited for older or medically frail patients. It also requires only a half-matched donor instead of a full match, significantly expanding access for individuals living with sickle cell disease (搜索), who often have fewer matched donors available. This type of transplant still carries the risk of graft-versus-host disease (搜索) (GVHD), but at a lower rate than previously observed.
Gene therapy, approved in 2023 by the U.S. Food and Drug Administration for patients 12 years and older with sickle cell disease (搜索), uses intensive conditioning followed by an infusion of a patient's own genetically modified and normally functioning stem cells.
Modeling Methodology and Key Findings
The researchers used a decision-analytic model to compare the cost-effectiveness of gene therapy, NMAC-HID allo-HSCT, and standard of care for patients with sickle cell disease (搜索) aged 18 years or more. They projected outcomes over a patient's lifetime across all accepted willingness-to-pay thresholds. To assess cost-effectiveness, the team determined quality-adjusted life-years (QALYs) and net monetary benefit (NMB).
In the base case, which accounted for key adverse events including GVHD and treatment failure, the results for adult patients receiving treatment in the United States were as follows:
- Gene therapy accrued 22.1 QALYs at a cost of $2.75 million
- NMAC-HID allo-HSCT accrued 20.1 QALYs at a cost of $1.15 million
- Standard of care accrued 14.3 QALYs at a cost of $1.22 million
The incremental NMBs for NMAC-HID allo-HSCT were $657,000 and $1,403,000 when compared to standard of care and gene therapy, respectively.
The researchers based the NMAC-HID allo-HSCT model on results from the phase II trials of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1507) and of the Vanderbilt Global Haploidentical BMT Learning Collaborative (VGHLC).
Gene Therapy Price Thresholds
The analysis determined that, in the United States, the threshold price for gene therapy — when compared to NMAC-HID allo-HSCT — is $627,000 or $740,000, based on VGHLC and BMT CTN 1507 data, respectively. This represents a 66% to 71% reduction from gene therapy's current price and falls below the $1.3 million cost suggested by the Institute for Clinical Economic Review. Using standard care as the comparator, the US threshold price for gene therapy was $1.4 million.
"No matter how much we adjusted from base case assumptions or accounted for uncertainty, NMAC-HID allo-HSCT delivered the best clinical value for cost," said Dr. Goshua.
The authors also extended the analysis internationally to India, Nigeria, and Tanzania, where cost-effective price thresholds for gene therapy were far lower than in the US. Against NMAC-HID allo-HSCT, estimated gene therapy thresholds ranged from $24,000 to $35,000 at supply-side cost-effectiveness thresholds, reflecting the different health-system economics and resource constraints in those settings.
Clinical Implications and Patient-Centered Considerations
Dr. Goshua emphasized that the findings should guide policy rather than restrict patient access. "From a patient perspective, there are multiple trade-offs across sickle cell treatment options, including differences in eligibility, timing, and a patient's individual values and preferences. From a policy perspective, understanding the cost-effectiveness of all these available treatments can equip governments to make informed, strategic decisions about how to invest in and support the health of their populations living with sickle cell disease (搜索)."
He added a critical caveat: "That said, it is important for individuals living with sickle cell disease (搜索) to have access to as many treatments as possible; gene therapy may be the best option for many patients, and these data should not be interpreted as reason to deny them coverage. Treating physicians must continue to discuss all options with patients in the context of shared patient-physician decision making."
Study Limitations
The analysis has several limitations acknowledged by the authors. Long-term safety and efficacy data for both gene therapy and NMAC-HID allo-HSCT remain limited, and the model lacked patient-level data across trials. It also assumed that patients pursuing curative treatment had a viable donor and no prohibitive donor-specific antibodies, did not explicitly include fertility preservation costs, and relied on public gene therapy list prices rather than confidential payer-negotiated prices.
"Globally, the cost and access to stem cell transplantations are substantial barriers for many," said Dr. Goshua. "The price thresholds suggested in our U.S. and expanded international analyses may help guide local governmental investment for both curative therapies in sickle cell disease (搜索)."